BioRun
Latest round
- Series A
Last raised
- Jan 2024
Total raised
- Undisclosed
Investors
- 4
About BioRun
Established in 2011 and based in Wuhan, China, BioRun operates as a biotechnology company dedicated to providing services such as gene cloning and protein expression vector construction. It has sub-branch offices in Sanya and Huanggang. The company acquired PCT US patent authorization and has applied for more than ten patents. The founder and CEO of the company, Yang Li graduated from Wuhan University. In 2022, the company obtained the title of High-tech Enterprise. The company mainly provides platforms for the research and application of functional genes in animals and plants. The platforms include genetic transformation platform, detection platform, protein platform, and synthetic biology platform. The company's platforms can provide services such as gene cloning, gene synthesis, DNA cloning and construction, and crop transgenic research. BioRun also provides an e-commercial platform named BioRun Strict Selection, which provides products such as molecular biology agents, culture media, and biological reagents. The service targets include scientific research institutes and seed companies. The company will build multi-omics platform.
Who invested in BioRun
4 investors across 1 round
See all investors in BioRun
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 5, 2024
Amount
Undisclosed
Investors
Questions about BioRun
Who invested in BioRun?
BioRun has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioRun raised?
BioRun has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BioRun last raise money?
BioRun's most recent round on record is a Series A, in Jan 2024.
What does BioRun do?
Established in 2011 and based in Wuhan, China, BioRun operates as a biotechnology company dedicated to providing services such as gene cloning and protein expression vector construction.
Where is BioRun headquartered?
BioRun is headquartered in Wuhan, China.
Which VCs invest in companies like BioRun?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BioRun's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BioRun? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.